Free Newsletter
Lilly's Lechleiter: 'We're a biotech'
Tomorrow is the first day on the CEO job for Eli Lilly's John Lechleiter (photo), and to mark the occasion, the Associated Press profiled the Harvard-trained chemist. The man behind the title walks to work, over a mile each way. Roman Catholic, he went to parochial schools with his eight siblings. He shared the attic of the family home with four brothers.
These days, he's a blogger. He updates his in-house web log weekly, using his BlackBerry to write new entries. And he's a longtime Lilly insider who's facing big expectations when he takes over the company tomorrow. Lechleiter ascends at a time when Lilly is under siege by states and the feds for alleged Zyprexa marketing infractions and when patents are running out for it and other big products. Signs of the challenge ahead: "In a way, we're a biotech company," Lechleiter told the Associated Press, reaching for the label that so many drug makers with pipeline worries would like to apply to themselves. "Hidden within what's called a large pharma company."
- read the AP article in BusinessWeek
Related Articles:
Did Lilly chief support off-label promos?
Lilly joins pharma's new-CEO club
Lilly developing biotech drugs the old-fashioned way
Comments
Best of luck to Mr. Lechleiter,regarding the Zyprexa scandal as lots of claimants have NOT been paid yet.
9+ more states still to deal.
The settlement with the feds could top $1 billion.
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Comments (1) | Post a comment